Company intelligence / Profile preview

RSV Corporation

Minato-ku, Tokyo, Japan

Ownership: Private
Development stage: Other

Overview

RSV Corporation is a clinical-stage biotechnology company based in Japan that specializes in the development of innovative antiviral therapies for Respiratory Syncytial Virus (RSV). Founded as a spin-off from the Institute of Medical Science at the University of Tokyo, the company focuses on addressing the high unmet medical need for effective RSV treatments in infants and the elderly. Its lead candidate, RSVC-001, is an orally bioavailable small molecule inhibitor designed to prevent viral entry by targeting the RSV fusion protein. The company aims to provide a safe and effective treatment option to reduce the global burden of RSV-related hospitalizations and severe respiratory disease.

Therapeutic areas: Infectious Diseases
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on RSV Corporation.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RSV Corporation.

Explore the full profile